Comparison of 2mg and 5mg Nalbuphine as an adjuvant to Ropivacaine in spinal anaesthesia for patients Undergoing elective lower limb surgeries
Not Applicable
- Conditions
- Health Condition 1: O- Medical and SurgicalHealth Condition 2: 8- Other Procedures
- Registration Number
- CTRI/2021/01/030645
- Lead Sponsor
- Veer Surendra Sai institute of medical science and research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA grade 1&2
Planned for elective lower limb surgeries
Exclusion Criteria
Pregnant patients
Patients with co morbidities like hypertension and diabetes
Patient having contraindications to SAB
Weight more than 100kg and less than 30kg
Patients receiving CNS depressant drugs
Patient having cardiac renal respiratory disease
H/o adverse reactions to Ropivacaine and Nalbuphine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intrathecal Nalbuphine can be used as a good adjuvant to subarachnoid block as it can prolong both sensory and motor blockade with minimal side effects <br/ ><br>Low dose Nalbuphine (2mg) will be producing equal motor and prolonged analgesia as compared to 5mg of Nalbuphine with lesser side effectsTimepoint: 4-6hours
- Secondary Outcome Measures
Name Time Method Adverse effectsTimepoint: Within 10 hour after spinal anaesthesia